FDA review warns of possible cardiovascular risk with Chantix

12/12/2012 | MedPage Today (free registration)

An updated FDA review found that the smoking-cessation drug Chantix was associated with higher risk of myocardial infarction, stroke and death compared with placebo, although the difference in risk was not statistically significant. Chantix was also linked to depression and suicidal tendencies, but recent studies showed that the drug did not raise the risk of psychiatric conditions.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President, Science and Regulatory Affairs
American Beverage Association
Washington, DC
Senior Manager of Medical Management
Network Health
Medford, MA
Columbus, OH
Manager, Medical Management
Network Health
Medford, MA
Medical Director - Cataract
Santa Ana, CA